The Must-have Household Disease Prevention! GIGABYTE Apply Special Offers on Laptops for Work and Entertainment from Home
26.3.2020 13:00:00 EET | Business Wire | Press release
(GIGABYTE) As the new Coronavirus rages around the world, many countries have announced lockdown of cities or regions. Many enterprises have begun implementing Work-from-Home policies to protect employees from infection. For those who are already working from home, you fed-up with the performance of your old computer? As for those who have not been quarantined, are you well-prepared to work from home? As a leading laptop manufacturer, GIGABYTE now provides selection guides for different consumer groups and offers excellent discounts. With GIGABYTE’s ultra-performance laptops, not only can you work effortlessly from home, but can also enjoy binge-watching and gaming thanks to their excellent display and immersive sound effects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005025/en/
(Photo: GIGABYTE)
As the pandemic spreads, how to work efficiently from home as well as pass time has become the focus of many people. "In addition to laptops’ performance and image quality, what concerns people working from home includes network quality, having enough ports to connect to devices such as screens, convenience of use in every corner of the house (such as the sofa or bed), and the long battery life," says Steven Chen, VP of GIGABYTE Mobility Product Business Group.
Wireless signal too weak? Not enough ports?
GIGABYTE’s AERO and AORUS Series have taken all these concerns into account. For the wireless network coverage and communication quality issues caused by the home environment, GIGABYTE combines Killer Wireless xTend technology to turn its laptops into a wireless range extender, which extends both wired and wireless networks. The latter can even be extended to cover 90 square meters, eliminating all household notspots. Besides, both series have up to nine external ports, including audio and video transmission ones for Display, HDMI, and Thunderbolt. Want to connect to a larger screen at home? You don’t have to waste money on a bunch of adapters anymore. GIGABYTE’s laptops also feature 94Wh batteries, the high capacity of which is twice that of other products in the industry, allowing laptops to work for more than 8-9 hours in high-performance mode.
Fight the Coronavirus together! Special offers for Intel Gen9 high-performance models!
Amid the Coronavirus outbreak, GIGABYTE has launched discounts for different consumer groups, directly launching models that have received both domestic and international recognition, including European Hardware Association’s Best Notebook 2019 and Taiwan Excellence Awards. Since all the discounted laptops have Intel's ninth-generation Core i7 processor, NVIDIA RTX / GTX series graphics cards and are equipped with Windows 10, whether you are someone who has to work from home or just looking for fun, you can easily find a laptop with favorable discounts that fits your personal needs!
For creators pursuing 4K UHD of HDR400 on video/audio quality - AERO 15 OLED
The AERO 15 OLED features the AMOLED 4K UHD screen, high color saturation of HDR400 Certified, ultra-high contrast, 3mm narrow border, ultra-rich and colorful image quality, and supports 100% DCI-P3 color gamut, which is far better than ordinary LCD screens’ 40% NTSC color performance. Having acquired the TÜV Rheinland's hardware low blue light certification, the AERO 15 OLED can reduce harmful blue light by more than 10% compared with ordinary screens, and protect eyes from long-hours of creative work and binge-watching. With the only X-Rite Pantone certified screen in the industry, each panel of the AERO series undergoes independent color correction, allowing its screen color to match the accuracy of the Pantone Matching System!
For people focusing on both business and entertainment – AERO 15 Classic
With a sharp and appealing appearance, the business-like AERO 15 Classic features a thickness of 1.8cm and a weight of 2.0 kg, allowing high portability for working outside once the pandemic ends. Moreover, the performance of NVIDIA GTX / RTX or above is also more than enough to play games. The AERO 15 Classic comes in various panel options, such as the 4K UHD or 144Hz/240Hz gaming monitors, allowing you to enjoy a 4K high image quality or a high refresh rate above 144Hz and to play games without stuttering. It also features X-Rite Pantone certified screens with each panel undergoing independent color correction.
For real hardcore gamers – AORUS 15
The AORUS 15 is the most powerful laptop with a thickness below 2.4cm, Intel Core i7 processor, the highest NVIDIA RTX 2060 graphics card, and unique WINDFORCE Infinity cooling technology, even the waste heat generated by the CPU and GPU can be processed independently without compromising performance. Its sharp 240Hz gaming specifications feature a super high refresh rate, allowing 3A game masterpieces to run smoothly without delay or lag.
For people pursuing high storage capacity with 144Hz display - AORUS 5/7
With the super-optimal 144Hz screen rarely seen among gaming laptops of the same level, the AORUS5/7 weighs 2.15KG and has a thickness of only 23mm, allowing gamers to enjoy lightweight and portability. Its hybrid SSD+HDD drive provides both access speed and large capacity, up to 3 storage interfaces. With a capacity of up to 6TB, you can store large amounts of games or videos without the need of external hard drives.
*For more information, please visit GIGABYTE/AORUS website:
|
Germany (Deutsch) |
|
|
France (Français) |
|
|
Spain (Español) |
|
|
United Kingdom (English) |
|
|
Netherlands (Dutch) |
*For more photos, please download here: https://drive.google.com/open?id=1OpkPIRJ6Pc1vSTnW7IehumMRE2YcqHax
GIGABYTE also offers quantity discounts to enterprises. In addition to greater discounts, enterprises can enjoy an extended warranty. For more information, please contact: gswe@gigabyte.com
About GIGABYTE
GIGABYTE is an engineer, visionary, and leader in the world of tech that uses its hardware expertise, patented innovations, and industry leadership to create, inspire and advance. Renowned for over 30 years of award-winning excellence, GIGABYTE is a cornerstone in the HPC community, providing businesses with server and data center expertise to accelerate their success. At the forefront of evolving technology, GIGABYTE is devoted to inventing smart solutions that enable digitalization from edge to cloud, and allow customers to capture, analyze, and transform digital information into economic data that can benefit humanity and "Upgrade Your Life". Please visit https://www.gigabyte.com/ for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005025/en/
Contact information
Media:
Kristy Chen (kristy.chen@gigabyte.com)
Claire Lai (Claire.lai@gigabytenb.com )
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
